Amylyx Pharmaceuticals Statistics
Total Valuation
AMLX has a market cap or net worth of $743.21 million. The enterprise value is $565.23 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AMLX has 89.17 million shares outstanding. The number of shares has increased by 15.02% in one year.
| Current Share Class | 89.17M |
| Shares Outstanding | 89.17M |
| Shares Change (YoY) | +15.02% |
| Shares Change (QoQ) | +4.02% |
| Owned by Insiders (%) | 9.01% |
| Owned by Institutions (%) | 66.67% |
| Float | 47.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -2,972.25 |
| Forward PS | n/a |
| PB Ratio | 4.41 |
| P/TBV Ratio | 4.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.72, with a Debt / Equity ratio of 0.04.
| Current Ratio | 8.72 |
| Quick Ratio | 8.45 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -87.42% and return on invested capital (ROIC) is -56.18%.
| Return on Equity (ROE) | -87.42% |
| Return on Assets (ROA) | -46.74% |
| Return on Invested Capital (ROIC) | -56.18% |
| Return on Capital Employed (ROCE) | -113.74% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.53M |
| Employee Count | 123 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -635,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +317.09% in the last 52 weeks. The beta is -0.45, so AMLX's price volatility has been lower than the market average.
| Beta (5Y) | -0.45 |
| 52-Week Price Change | +317.09% |
| 50-Day Moving Average | 7.02 |
| 200-Day Moving Average | 4.99 |
| Relative Strength Index (RSI) | 60.81 |
| Average Volume (20 Days) | 1,002,128 |
Short Selling Information
The latest short interest is 7.19 million, so 8.07% of the outstanding shares have been sold short.
| Short Interest | 7.19M |
| Short Previous Month | 7.47M |
| Short % of Shares Out | 8.07% |
| Short % of Float | 15.02% |
| Short Ratio (days to cover) | 4.53 |
Income Statement
In the last 12 months, AMLX had revenue of -$249,000 and -$187.60 million in losses. Loss per share was -$2.41.
| Revenue | -249,000 |
| Gross Profit | -94.52M |
| Operating Income | -196.98M |
| Pretax Income | -162.36M |
| Net Income | -187.60M |
| EBITDA | -196.30M |
| EBIT | -196.98M |
| Loss Per Share | -$2.41 |
Full Income StatementBalance Sheet
The company has $180.83 million in cash and $5.96 million in debt, giving a net cash position of $174.86 million or $1.96 per share.
| Cash & Cash Equivalents | 180.83M |
| Total Debt | 5.96M |
| Net Cash | 174.86M |
| Net Cash Per Share | $1.96 |
| Equity (Book Value) | 167.88M |
| Book Value Per Share | 1.88 |
| Working Capital | 165.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$165.65 million and capital expenditures -$36.23 million, giving a free cash flow of -$201.88 million.
| Operating Cash Flow | -165.65M |
| Capital Expenditures | -36.23M |
| Free Cash Flow | -201.88M |
| FCF Per Share | -$2.26 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | 79,106.43% |
| Pretax Margin | 75,596.39% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AMLX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.02% |
| Shareholder Yield | -15.02% |
| Earnings Yield | -25.35% |
| FCF Yield | -27.28% |
Dividend DetailsAnalyst Forecast
The average price target for AMLX is $12.00, which is 43.97% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.00 |
| Price Target Difference | 43.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 19.58% |
| EPS Growth Forecast (5Y) | -51.63% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AMLX has an Altman Z-Score of -0.67 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.67 |
| Piotroski F-Score | 3 |
